Institut Català de la Salut
[Glennie L] Medical Research Council Protein Phosphorylation & Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, UK. [Codina Solà M, Xunclà M, Garcia-Arumí E, Fidel Tizzano E, Lasa-Aranzasti A] Àrea de Genètica Clínica i Molecular, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca de Medicina Genètica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Aparicio Español G] Servei de Dermatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2024-09-18T13:56:56Z
2024-09-18T13:56:56Z
2024-07
Hyperkeratosis; Palmoplantar keratoderma
Hiperqueratosis; Queratodermia palmoplantar
Hiperqueratosi; Queratodermia palmoplantar
Palmoplantar keratoderma (PPK) is a multi-faceted skin disorder characterized by the thickening of the epidermis and abrasions on the palms and soles of the feet. Among the genetic causes, biallelic pathogenic variants in the FAM83G gene have been associated with PPK in dogs and humans. Here, a novel homozygous variant (c.794G>C, p.Arg265Pro) in the FAM83G gene, identified by whole exome sequencing in a 60-year-old female patient with PPK, is reported. The patient exhibited alterations in the skin of both hands and feet, dystrophic nails, thin, curly and sparse hair, long upper eyelid eyelashes, and poor dental enamel. FAM83G activates WNT signalling through association with ser/thr protein kinase CK1α. When expressed in FAM83G−/− DLD1 colorectal cancer cells, the FAM83GR265P variant displayed poor stability, a loss of interaction with CK1α and attenuated WNT signalling response. These defects persisted in skin fibroblast cells derived from the patient. Our findings imply that the loss of FAM83G-CK1α interaction and subsequent attenuation of WNT signalling underlie the pathogenesis of PPK caused by the FAM83GR265P variant.
G.P.S. was supported by the UKRI Medical Research Council (grant MC_UU_00018/6) and the pharmaceutical companies supporting the Division of Signal Transduction Therapy (Boehringer Ingelheim, GlaxoSmithKline, Merck-Serono). L.G. was supported by MRC PPU PhD studentship.
Article
Versió publicada
Anglès
Pell - Malalties - Aspectes genètics; Transducció de senyal cel·lular; Fibroblasts; DISEASES::Skin and Connective Tissue Diseases::Skin Diseases::Keratosis::Skin and Connective Tissue Diseases::Skin Diseases::Keratoderma, Palmoplantar; PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Signal Transduction::Wnt Signaling Pathway; ANATOMY::Cells::Connective Tissue Cells::Fibroblasts; ENFERMEDADES::enfermedades de la piel y tejido conjuntivo::enfermedades de la piel::queratosis::enfermedades de la piel y tejido conjuntivo::enfermedades de la piel::queratodermia palmoplantar; FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::transducción de señales::vía de señalización Wnt; ANATOMÍA::células::células del tejido conectivo::fibroblastos
Royal Society
Open Biology;14(7)
https://doi.org/10.1098/rsob.240075
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - VHIR [1665]